Modeling schizophrenia endophenotypes in drosophila melanogaster: effects of ketamine on anxiety, aggression, locomotion and inflammatory responses

Abdulrahman Adesola Bello, Royhaan Olamide Folarin

Abstract


Schizophrenia presents a significant challenge in mental health, characterized by a profound distortion of reality, often accompanied by hallucinations, delusions, cognitive deficits and neuroinflammatory processes. Ketamine has been widely used as a pharmacological agent to model schizophrenia symptoms in both human and animal studies. However, the potential of ketamine to induce schizophrenia-like phenotypes in Drosophila melanogaster remains under-investigated. This study therefore investigated the effects of ketamine on anxiety, aggression, locomotor activities, and inflammatory response in Drosophila melanogaster in a bid to develop a pharmacological model of schizophrenia in Drosophila.Virgin male and female Oregon-R flies were collected after eclosion and exposed to four different concentrations of ketamine (100, 250, 500, 1000 µg/mL) for 1 week under standard laboratory conditions (22-25°C, 50-60% humidity). Experimental groups consisted of 10 vials each containing 10 flies each. Anxiety, aggression and locomotory functions were assessed behaviorally through the open field, aggression, and rapid iterative negative geotaxis (RING) assays. Pro-inflammatory and astrogliotic responses were measured immunohistochemically using Tumor necrosis factor-alpha (TNF-α) and Glial fibrillary acidic protein (GFAP) antibodies. General neuronal architecture was evaluated using the H&E histological staining techniques.The results showed a dose-dependent induction of aggressive behavior. Motor function assays demonstrated that ketamine impaired these functions in a dose-dependent manner. Survival assays indicated that higher doses of ketamine reduced survival rates. Immunohistochemical analysis revealed a dose-dependent increase in TNF-α and GFAP mean fluorescence intensity across the treatment groups, indicating upregulation of TNF-α and GFAP expressions. This suggests a robust pro-inflammatory and astrogliotic response to ketamine administration, aligning with the emerging neuroinflammatory endophenotype theory of schizophrenia aetiology and its experimental modeling. Histological analysis displayed significant dose-dependent histopathological changes, including increased cell loss and vacuolization at higher ketamine concentrations.In conclusion the findings suggest that ketamine has potential as a pharmacological model of schizophrenia in Drosophila. Overall, these results contribute to understanding of how ketamine influence key behavioral and neurobiological parameters, offering insights into their potential roles in inducing schizophrenia-like phenotypes like altered behavior and histopathology. Keywords: Ketamine, Drosophila melanogaster, Neuroinflammation, TNF-α, Schizophrenia, GFAP. Received on, 22 January 2025 Accepted on, 06 April 2025 Published on, 12 May 2025

Keywords


Ketamine, Drosophila melanogaster, Neuroinflammation, TNF-a, GFAP, Schizophrenia, Aggression, Anxiety

Full Text:

PDF

References


Hany M, Rehman B, Azhar Y, Chapman J. Schizophrenia [Internet]. StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539864/

Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Vol. 23, Molecules. 2018.

Zorumski CF, Izumi Y, Mennerick S. Ketamine: NMDA receptors and beyond. Journal of Neuroscience. 2016;36(44).

Beck K, Hindley G, Borgan F, Ginestet C, McCutcheon R, Brugger S, et al. Association of Ketamine with Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis. Vol. 3, JAMA Network Open. 2020.

Frohlich J, Van Horn JD. Reviewing the ketamine model for schizophrenia. Vol. 28, Journal of Psychopharmacology. 2014.

Mosquera FEC, Guevara-Montoya MC, Serna-Ramirez V, Liscano Y. Neuroinflammation and Schizophrenia: New Therapeutic Strategies through Psychobiotics, Nanotechnology, and Artificial Intelligence (AI). J Pers Med. 2024 Apr 6;14(4):391.

Kölliker-Frers R, Udovin L, Otero-Losada M, Kobiec T, Herrera MI, Palacios J, et al. Neuroinflammation: An Integrating Overview of Reactive-Neuroimmune Cell Interactions in Health and Disease. Vol. 2021, Mediators of Inflammation. 2021.

Warren N, O’Gorman C, Horgan I, Weeratunga M, Halstead S, Moussiopoulou J, et al. Inflammatory cerebrospinal fluid markers in schizophrenia spectrum disorders: A systematic review and meta-analysis of 69 studies with 5710 participants. Schizophr Res. 2024;266.

Laskaris LE, Di Biase MA, Everall I, Chana G, Christopoulos A, Skafidas E, et al. Microglial activation and progressive brain changes in schizophrenia. Vol. 173, British Journal of Pharmacology. 2016.

Li D, Liu X, Liu T, Liu H, Tong L, Jia S, et al. Neurochemical regulation of the expression and function of glial fibrillary acidic protein in astrocytes. Vol. 68, GLIA. 2020.

McAlpine FE, Tansey MG. Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease. J Inflamm Res. 2008;1.

Jeibmann A, Paulus W. Drosophila melanogaster as a model organism of brain diseases. Vol. 10, International Journal of Molecular Sciences. 2009.

Mariano V, Achsel T, Bagni C, Kanellopoulos AK. Modelling Learning and Memory in Drosophila to Understand Intellectual Disabilities. Vol. 445, Neuroscience. 2020.

Folarin R, Kayode A, Adenowo T, Adeyanju M, Olugbode J, Obadeyin E. GEOTACTICAL AND NEUROCHEMICAL PHENOTYPES OF DROSOPHILA MELANOGASTER FOLLOWING NIGELLA SATIVA EXPOSURE. 2019.

Koksal PM, Gürbüzel M. Analysis of genotoxic activity of ketamine and rocuronium bromide using the somatic mutation and recombination test in Drosophila melanogaster. Environ Toxicol Pharmacol. 2015;39(2).

Linford NJ, Bilgir C, Ro J, Pletcher SD. Measurement of lifespan in Drosophila melanogaster. Journal of Visualized Experiments. 2013;(71).

Bawani SS, Anandhi DU. GC-MS Analysis of Nigella Sativa Seed Extract and Its Ameliorative Effects on Transgenic Drosophila Model of Parkinson Disease. Int J Innov Sci Res Technol. 2021;6(4).

Soibam B, Mann M, Liu L, Tran J, Lobaina M, Kang YY, et al. Open-field arena boundary is a primary object of exploration for Drosophila. Brain Behav. 2012;2(2).

Dierick HA. A method for quantifying aggression in male drosophila melanogaster. Nat Protoc. 2007;2(11).

Karmakar P, Mishra M. Histological Analysis of the Drosophila Head with Special Reference to the Eye and Brain. In 2020. p. 39–49.

Zou X, Patterson TA, Sadovova N, Twaddle NC, Doerge DR, Zhang X, et al. Potential neurotoxicity of ketamine in the developing rat brain. Toxicological Sciences. 2009;108(1).

Franceschelli A, Sens J, Herchick S, Thelen C, Pitychoutis PM. Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and “depressed” mice exposed to chronic mild stress. Neuroscience. 2015;290.

Simon P, Dupuis R, Costentin J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behavioural Brain Research. 1994;61(1).

Ye L, Ko CY, Huang Y, Zheng C, Zheng Y, Chou D. Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission. Neuropharmacology. 2019;157.

Imre G, Fokkema DS, Boer JAD, Ter Horst GJ. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull. 2006;69(3).

Chen WC, Wang TS, Chang FY, Chen PA, Chen YC. Age, Dose, and Locomotion: Decoding Vulnerability to Ketamine in C57BL/6J and BALB/c Mice. Biomedicines. 2023;11(7).

Moulin TC, Stojanovic T, Rajesh RP, Pareek T, Donzelli L, Williams MJ, et al. Effects of Transient Administration of the NMDA Receptor Antagonist MK-801 in Drosophila melanogaster Activity, Sleep, and Negative Geotaxis. Biomedicines. 2023;11(1).

Subedi L, Lee SE, Madiha S, Gaire BP, Jin M, Yumnam S, et al. Phytochemicals against TNFα-mediated neuroinflammatory diseases. Vol. 21, International Journal of Molecular Sciences. 2020.

Wang N, Yu HY, Shen XF, Gao ZQ, Yang C, Yang JJ, et al. The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus. Ups J Med Sci. 2015;120(4).

Li Y, Shen R, Wen G, Ding R, Du A, Zhou J, et al. Effects of ketamine on levels of inflammatory cytokines IL-6, IL-1β, and TNF-α in the hippocampus of mice following acute or chronic administration. Front Pharmacol. 2017;8(MAR).

Geuking P, Narasimamurthy R, Basler K. A genetic screen targeting the tumor necrosis factor/eiger signaling pathway: Identification of drosophila TAB2 as a functionally conserved component. Genetics. 2005;171(4).

Keilhoff G, Becker A, Grecksch G, Wolf G, Bernstein HG. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience. 2004;126(3).

Stenovec M. Ketamine alters functional plasticity of astroglia: An implication for antidepressant effect. Life. 2021;11(6).

Penkowa M, Camats J, Giralt M, Molinero A, Hernández J, Carrasco J, et al. Metallothionein-I overexpression alters brain inflammation and stimulates brain repair in transgenic mice with astrocyte - Targeted interleukin-6 expression. Glia. 2003;42(3).

Liu JR, Baek C, Han XH, Shoureshi P, Soriano SG. Role of glycogen synthase kinase-3β in ketamine-induced developmental neuroapoptosis in rats. Br J Anaesth. 2013;110(SUPPL.1).




DOI: https://dx.doi.org/10.21622/AMPDR.2025.05.1.1202

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 Abdulrahman Adesola Bello, Royhaan Olamide Folarin


Advances in Medical, Pharmaceutical and Dental Research

E-ISSN: 2812-4898

P-ISSN: 2812-488X

 

Published by:

Academy Publishing Center (APC)

Arab Academy for Science, Technology and Maritime Transport (AASTMT)

Alexandria, Egypt

ampdr@aast.edu